IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE OREXO AB and OREXO US, INC., Plaintiffs, ACTA VIS ELIZABETH LLC
More Options For Opioid Overdose: Nasal Naloxone On Brink Of OTC Use, While Opiant And Orexo Stay Rx To Counter High-Potency Opioids :: Pink Sheet
Opioid Use Disorder Market 2030 provides an in-depth insight of Sales and Trends Forecast to 2030 | Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc.
Type headline here
Rebateable Labelers October 2021
Teva Can Challenge Validity of Orexo Patent (Corrected)
Opioid Use Disorder Market Analysis to 2027 - Hikma Pharmaceuticals, Teva Pharmaceuticals, MediciNova, Orexo, Camurus, Omeros
Troubled Teva feels the heat from Israel, bondholders as shares continue to dive | Fierce Pharma
Allergan can finally sell its losing stake in Teva. Will it? | Fierce Pharma
Orexo seeks approval of nasal high-dose opioid rescue medicine
Type headline here
Opioid Use Disorder Market Is Booming Worldwide 2023-2030 | Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd. - Digital Journal
Orexo backs up new digital therapeutic launches with social, online marketing | Fierce Pharma
Orexo unveils nasal EpiPen rival, sets sights on 2022 clinical trial | Fierce Pharma
Emerging markets M&A is risky, and Teva's Rimsa debacle shows it | Fierce Pharma
Type headline here
Annual Report
Orexo acquires rights to commercialise alcohol use disorder digital therapy
Teva Wins Patent Dispute Over Orexo's Opioid-Treatment Drug - BNN Bloomberg
Cancer Pain Market predicted to improve enormous healthcare
Orexo enters patent infringement litigation against Actavis
Taylor Gibbons - Executive Sales Specialist - Teva Pharmaceuticals | LinkedIn
OREXO AB (PUBL)
Full Year Report incl. Q4 2017
Teva Can Challenge Validity of Orexo Patent (Corrected)
Taylor Gibbons - Executive Sales Specialist - Teva Pharmaceuticals | LinkedIn
